Stock fact sheet · data as of
Kazia Therapeutics Ltd ADR (KZIA): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · Australia · ADR · Speculative / Distressed
Is KZIA undervalued?
At 7.40 (close of 16 Oct 2026), KZIA has no GLS fair value: every one of the nine models needs a positive input (the company lost money over the last twelve months, EPS -4.97, it pays no dividend and its debts exceed what its assets would fetch), so the margin of safety is blank and the Wheel Score cannot be computed. Our screens leave the stock out at the first rule. What can be said from the nightly row is below.
The nightly engine files KZIA under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for KZIA
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -5.82 | -179% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 33.67 | +355% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Kazia Therapeutics Ltd ADR scores only 3 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.8/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.
Returns on capital are high - ROIC 261.9%, ROE 249.4%, ROA -341.6% - with debt at -0.05 times equity and negative free cash flow.
Kazia Therapeutics Ltd ADR pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 7/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | 261.9% |
|---|---|---|---|
| GLS Moat | 1.8 / 10 | ROE | 249.4% |
| Debt / equity | -0.05 | ROA | -341.6% |
| Free-cash-flow yield | -52.7% | Payout ratio | 0% |
| Institutions | 7 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 33: Weak
With a Wheel Score of 33 Kazia Therapeutics Ltd ADR sits in the Weak band. The parts - Value 13/25, Health 7/20, Moat 3/15, Premium 5/20, Stability 6/20 - show where: Moat (3/15) scores lowest.
Implied volatility is 272%, far above the range the wheel strategy is built for. The premium looks generous; the Wheel Score gives it only 5 of 20 Premium points because moves of that size can blow through any strike. Chain open interest is 2,527 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 386k shares a day on a market cap of $12M, with a beta of 2.27 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 6 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 7 / 20 | Piotroski 3/9 | |
| Moat | 3 / 15 | moat 1.8/10 | |
| Premium | 5 / 20 | implied volatility 272% | |
| Stability | 6 / 20 | 386k shares/day, $12M cap, beta 2.27 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
No upcoming earnings date is recorded for KZIA in the nightly calendar.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Kazia Therapeutics Ltd ADR by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| ACTU Actuate Therapeutics Inc | 0.4999 | 0.5399 | +7% | 32No options | $12M |
| AEON AEON Biopharma, Inc. | 0.2430 | - | - | 27No options | $12M |
| PASG Passage Bio, Inc. | 3.66 | 6.70 | +45% | 33No options | $12M |
| INAB IN8bio, Inc. | 1.19 | 5.49 | +78% | 36No options | $12M |
| PLRZ Polyrizon Ltd. | 10.41 | 0.8121 | -1182% | 9No options | $12M |
| ENSC Ensysce Biosciences, Inc. | 0.5979 | 0.0551 | -986% | 19No options | $12M |
| SYBX Synlogic, Inc. | 1.02 | 1.18 | +14% | 28No options | $12M |
| CTXR Citius Pharmaceuticals, Inc. | 0.4600 | 0.9200 | +50% | 45Weak | $13M |
| ANEB Anebulo Pharmaceuticals, Inc. | 0.3100 | 0.3396 | +9% | 26No options | $13M |
| CLRB Cellectar Biosciences, Inc. | 1.19 | 4.39 | +73% | 39No options | $11M |
| VICP Vicapsys Life Sciences, Inc. | 0.4000 | - | - | 27No options | $13M |
| DARE Dare Bioscience, Inc. | 0.7400 | 0.1776 | -317% | 13No options | $11M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about KZIA
Is KZIA undervalued right now?
The GLS models could not value KZIA (the company lost money over the last twelve months, EPS -4.97, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 7.40 against.
What is the Wheel Score of KZIA and what does it mean?
KZIA scores 33 out of 100 (Weak). The Wheel Score blends the margin of safety (25 points), Piotroski health (20), the GLS moat (15), the option premium on offer (20) and trading stability (20) into one number that ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned. 80 and above is Prime, 65-79 Good, 50-64 Fair, under 50 Weak.
What is the GLS fair value for KZIA?
None of the nine GLS models produced a positive value for KZIA (the company lost money over the last twelve months, EPS -4.97, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does Kazia Therapeutics Ltd ADR report earnings next?
No upcoming earnings date is recorded for KZIA in our calendar as of 16 Oct 2026; the Calendars page is refreshed every morning.
Does KZIA have listed options, and how liquid are they?
Yes. The nightly snapshot found 88 listed contracts with 2,527 open interest across all expiries and implied volatility of 272% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.